Navigation Links
Medication May Improve Scar Healing
Date:4/9/2009

Juvista scores well for skin appearance in 3 trials

THURSDAY, April 9 (HealthDay News) -- The drug avotermin (brand name Juvista) seems to improve the healing of skin scars, according to three new studies.

Some volunteers had avotermin (Human Recombinant TGFa3) administered to their skin before wounding and again 24 hours later to both sides of 1-centimeter incisions that went all the way through the skin of the upper inner arm to the depth of the underlying muscle. Identical wounds were inflicted on other volunteers who received a placebo or standard wound care.

Two studies found that patients who received avotermin scored an average of five points higher on a visual 100-point scale of scar appearance after six months, and an average of eight points higher after one year.

The third study found that all concentrations of avotermin produced significantly improved total scar appearance scores versus placebo -- from 15 points at the 5 nanogram dose up to 64 points at the 500 nanogram dose. The researcher said 60 percent of scars treated with avotermin showed 25 percent or less abnormal orientation of the collagen fibers in the skin, compared with 33 percent of scars treated with placebo.

"Results of these phase 1-2 studies show that avotermin is a new class of prophylactic medicine promoting the regeneration of healthy skin and improving scar appearance compared with controls," according to Mark Ferguson, of the University of Manchester, U.K., and colleagues. "With low doses injected locally around the time of surgery, avotermin is a well tolerated and convenient treatment. These studies suggest that avotermin has potential to provide an accelerated and permanent improvement in scarring."

The study was published April 9 in The Lancet.

More information

The American Academy of Dermatology has more about scars.



-- Robert Preidt



SOURCE: The Lancet, news release, April 9, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
2. Manic phase of bipolar disorder benefits from breast cancer medication
3. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
4. Mayo Clinic study indicates medication for ADHD may help student outcomes
5. Diet and medications may assist prevention of prostate cancer
6. Delmarva Foundation Implements Medication Therapy Management Program in Maryland and DC
7. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
8. Moses Taylor Hospital Automates Medication Reconciliation
9. Cautious Optimism for New Alzheimers Medications, Reports the Harvard Mental Health Letter
10. Patients cant recall their medications to tell doctors
11. Patient Empowerment -- Medication Error
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Medication May Improve Scar Healing
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: